Video

Why Prolonged, Potent NK Cells May Transform Cancer Therapy

Source: Cell & Gene

In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics explained that his team’s technology enables NK cells to remain active and highly cytotoxic for weeks. This innovation combines functional longevity and strategic targeting of the immunosuppressive tumor microenvironment, opening doors for more effective, safer cancer treatment.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)